EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.21
−0.72%Next report
Analyst consensus
- Next report date
- Feb 25, 2027
- EPS estimate
- -$0.16
- Revenue estimate
- $137.5M
Latest reported
- Last report date
- Nov 2, 2026
- EPS actual
- -$0.36
- EPS estimate
- -$0.39
- Revenue actual
- $110.0M
- Revenue estimate
- $123.2M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 7
- EPS misses (12Q)
- 1
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +495.3%
- Revenue beats (12Q)
- 5
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 2, 2026 | -$0.39 | -$0.36 | Beat 8.03% | $110.0M |
| Aug 5, 2026 | -$0.09 | $0.60 | Beat 805.88% | $234.3M |
| Apr 30, 2026 | -$0.25 | $0.21 | Beat 184.00% | $156.1M |
| Oct 29, 2025 | -$0.12 | $1.06 | Beat 983.33% | $231.1M |
| Mar 3, 2025 | -$0.35 | $0.05 | Beat 114.29% | $189.3M |
| May 1, 2024 | -$0.86 | $0.59 | Beat 168.60% | $300.4M |
| Mar 6, 2024 | -$0.33 | -$0.77 | Miss -133.33% | $276.6M |
| Dec 11, 2023 | — | -$1.76 | — | $330.7M |
| Feb 27, 2023 | — | -$1.76 | — | $330.7M |
| Apr 28, 2022 | — | -$0.07 | — | $307.5M |
| Feb 24, 2022 | $4.27 | $4.50 | Beat 5.39% | $723.2M |
| Nov 4, 2021 | — | -$0.65 | — | $329.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 25, 2027